Information Provided By: 
Fly News Breaks for January 31, 2017
SYK, ZBH
Jan 31, 2017 | 11:58 EDT
Piper Jaffray analyst Matt O'Brien said he views Zimmer Biomet's (ZBH) relatively in-line guidance for FY17 to be "good enough," adding that organic growth is seen accelerating throughout the year and that the company has both operating and financial levers to pull for earnings growth. O'Brien, who expects Zimmer's valuation discount to peer Stryker (SYK) to narrow, would be a buyer of Zimmer shares and keeps an Overweight rating on the stock.
News For ZBH;SYK From the Last 2 Days
There are no results for your query ZBH;SYK
